Status:
COMPLETED
Novel Medication as a Potential Smoking Cessation Aid
Lead Sponsor:
University of Minnesota
Conditions:
Tobacco Use Disorder
Eligibility:
All Genders
25-55 years
Phase:
NA
Brief Summary
The purpose of this study is to provide preliminary information assessing if levomilnacipran may be effective at increasing smoking cessation rates.
Eligibility Criteria
Inclusion
- Be between 25 years old and 55 years old
- Smoke a minimum number of cigarettes per day
- Indicate motivation to quit smoking
Exclusion
- Current or history of medical or psychiatric conditions that could interfere with measures being studied or that could be affected by the study medication
- Use of medication that could interfere with measures to be studied or that could be expected to interact with levomilnacipran
- Are pregnant or breast feeding
- The investigators will evaluate if there are other reasons why someone may not be eligible to participate
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2017
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT02265367
Start Date
January 1 2015
End Date
May 1 2017
Last Update
April 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical and Translational Sciences Institute
Minneapolis, Minnesota, United States, 55455